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ABSTRACT 46 
 47 
Guidelines from the American National Comprehensive Cancer Network (NCCN) 48 
recommend neoadjuvant chemotherapy (NAC) to patients with locally advanced breast 49 
cancer (LABC) to downstage tumors before surgery.  However, only a small fraction 50 
(15-17%) of LABC patients achieve complete pathologic response (pCR), i.e. no 51 
residual tumor in the breast, after treatment.  Measuring tumor response during 52 
neoadjuvant chemotherapy can potentially help physicians adapt treatment thus, 53 
potentially improving the pCR rate.   54 
Recently, imaging biomarkers that are used to measure the tumor’s functional 55 
and biological features have been studied as pre-treatment markers for pCR or as an 56 
indicator for intra-treatment tumor response.  Also, imaging biomarkers have been the 57 
focus of intense research to characterize tumor heterogeneity as well as to advance our 58 
understanding of the principle mechanisms behind chemoresistance.  Advances in 59 
investigational radiology are moving rapidly to high-resolution imaging, capturing 60 
metabolic data, performing tissue characterization and statistical modelling of imaging 61 
biomarkers, with an endpoint of personalized medicine in breast cancer treatment.  In 62 
this commentary, we present studies within the framework of imaging biomarkers used 63 
to measure breast tumor response to chemotherapy.  Current studies are showing that 64 
significant progress has been made in the accuracy of measuring tumor response either 65 
before or during chemotherapy, yet the challenges at the forefront of these works 66 
include translational gaps such as needing large-scale clinical trials for validation, and 67 
standardization of imaging methods.  However, the ongoing research is showing that 68 
imaging biomarkers may play an important role in personalized treatments for LABC.          69 
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    INTRODUCTION AND BACKGROUND 70 
 71 
Recent guidelines by the National Comprehensive Cancer Network (NCCN) 72 
define locally advanced breast cancer (LABC) as stage 3 breast cancer [1].  Thus, large 73 
tumors greater than 5 cm with regional lymph node involvement or inoperable breast 74 
cancer, defined as having skin and/or chest wall involvement are locally advanced [1, 75 
2]. Incidence rates of LABC in the United States accounted for 12.4% of new breast 76 
cancer cases in 2015 and 8.5% of cases in the United Kingdom [3, 4].    Survival data 77 
from the SEER registry (Statistics, Epidemiology, and End-Results Program) in the 78 
United States have indicated poor survival outcomes  [5, 6]; mortality rates were 52% 79 
for stage 3A breast cancer and 48% for stage 3B disease [5].   Similarly, data from the 80 
United Kingdom showed that between 2002-2006, only 55.1% of women with stage 3 81 
breast cancer survived beyond 5-years (recent data unavailable) [7].  Poor survival 82 
outcomes are caused by factors associated with genetics, tumor heterogeneity, 83 
vascularity, oxygenation and some intrinsic molecular features such as estrogen 84 
receptor (ER) and human epidermal growth factor receptor-2 (Her2) expression.     85 
The recommended treatment course for LABC is neoadjuvant chemotherapy 86 
(NAC), followed by surgery, then radiation [1, 8].  Studies emerged in the 1970s 87 
demonstrating the benefit of pre-operative chemotherapy to downstage tumors before 88 
surgery, since reducing the tumor size and extent can make surgical excision possible 89 
[9] .   The additional benefit of using NAC includes enabling lumpectomy rather than 90 
total mastectomy, if for example there are clinical indications (tumor size and margins, 91 
nodal status and patient preference after NAC) [1, 9-12].  Neoadjuvant chemotherapy is 92 
also desirable since monitoring tumor response during therapy would allow potentially 93 
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adapting therapies based on clinical response [13, 14].  It has been shown that 94 
pathological complete response (pCR), defined as having no residual tumor after NAC 95 
can serve as a prognostic indicator for survival and is supported by work from the 96 
German Breast Group (GBG) who reported improved disease-free survival for luminal 97 
B/Her2-, Her2+ (non-luminal), and triple negative (ER-/PR-/Her2-) breast cancers that 98 
achieve pCR [15].  Furthermore, a meta-analysis of 3,182 locally advanced breast 99 
cancer patients demonstrated improved survival in patients who achieved pCR after 100 
neoadjuvant chemotherapy (overall survival=2.3-7.6 years) [16]. In another study, 87% 101 
of pCR patients survived beyond 5 years, in comparison to patients who demonstrated 102 
partial or no response [17].  The results of these studies suggest that pathology 103 
endpoints after neoadjuvant chemotherapy can provide vital information on survival 104 
outcomes and thus, pCR is in part, the desired clinical outcome for administering NAC.  105 
However, despite the significant improvements in treatment strategies over past 106 
decades, only a small fraction of patients will achieve pCR.   Previous studies have 107 
reported pCR rates of only 15.2%-17.4% following neoadjuvant chemotherapy [16, 18].  108 
With less than a quarter of treated patients achieving a complete pathological response, 109 
new ways of improving outcome and survival for patients with LABC are a real clinical 110 
challenge for the future.   111 
To address these challenges, there has been research interests in exploring new 112 
ways to assess intra-treatment responses to NAC as well in finding ways to predict the 113 
treatment response even before the use of chemotherapy; in other words, to make a 114 
prognosis for the presumed efficacy of the treatment.  A deeper understanding of tumor 115 
behavior and customizing treatments based on genetic, patient and other biological 116 
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information are referred to as precision medicine.  The tailoring of treatments is also 117 
termed personalized medicine.    118 
To help achieve this, a greater understanding is needed of tumor biology; the 119 
way the tumor influences for example, angiogenesis, drives cell proliferation and 120 
ultimately how the tumor cells die from chemotherapy are important considerations for 121 
precision medicine in oncology.  In this commentary, we present past and current 122 
studies focusing on imaging biomarkers in breast cancer.  123 
 124 
HALLMARKS OF CHEMORESISTANCE AND 125 
CHEMOEFFICACY 126 
 127 
 128 
Intertumor and Intratumor Heterogeneity Contributes to Chemoresistance 129 
 130 
Intertumor heterogeneity is, in part, caused by intrinsic variances in molecular 131 
features such as estrogen receptor (ER), progesterone receptor (PR) and human 132 
epidermal growth factor-2 receptor (Her2).  Data from 50,571 women in the United 133 
States indicated that 72.7% of women exhibit luminal A-like breast cancer; while 12.2% 134 
express basal-like breast cancers.  A smaller portion of patients exhibit luminal B-like 135 
breast cancer (10.3%); whereas only 4.6% of all breast cancer patients have Her2 136 
overexpressed (Her2+) breast cancer. [19].  These differences in tumor profiles can 137 
require different targeted therapies, such as Trastuzumab in the case of Her2 138 
overexpressed tumors.  Breast cancer subtypes also demonstrate variable responses to 139 
neoadjuvant chemotherapy [15, 20, 21].  Reports from over 6,000 patients have 140 
indicated that basal-type, and HER2+ breast cancers have the highest rate of pCR to 141 
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anthracycline- and taxane-based chemotherapies. In contrast, luminal A and luminal B 142 
breast cancers (i.e. ER+, PR+) are highly resistant to chemotherapy [15].  Rodent 143 
models have demonstrated that luminal breast cancer cells exhibit stem-cell-like 144 
behaviors that are genetically driven for tumor cell immortality, higher rates of 145 
differentiation, and rapid proliferation [22].  Some studies have also suggested that 146 
basal-type tumors have dysfunctional cell-repair mechanisms in comparison to luminal 147 
A and luminal B tumors that make it more susceptible to chemotherapy-induced DNA 148 
damage [23].          149 
Intratumor heterogeneity is another treatment resistance challenge.  It is 150 
characterized as a mixture of cells and stromal features that constitute tumor 151 
composition.  Tumors are also constructed from a variety of other cell-types such as 152 
fibroblasts, immune cells, adipocytes and normal breast epithelial cells [24, 25].    The 153 
complexity of intratumor heterogeneity is confounded by morphological differences such 154 
as enlarged or shrunken cell sizes from tumor cell proliferation and cycling.  These 155 
events also cause substructural alterations that result in condensed nuclear bodies and 156 
organelle reorganization [26]. Taken together, tumors are composed of disorganized 157 
and aberrant cells, and circulating biomolecules that are “woven” into a turbulent 158 
vascular scaffold and environment.  Other physiological conditions that lead to 159 
intratumor heterogeneity include fluctuating interstitial fluid, variable vascular perfusion 160 
and circulating biomolecules [27].  These aberrations inhibit effective delivery of 161 
chemotherapies and, thus, result in variable treatment response.   Taken together, the 162 
heterogeneous and tortuous tumor matrix is a significant treatment challenge in breast 163 
cancer [28]. 164 
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 165 
Mechanisms of Chemoefficacy 166 
 167 
One mechanism by which chemotherapy agents exert their therapeutic effect is 168 
by committing tumor cells to apoptosis [29, 30].  In comparison to other forms of cell 169 
death, such as necrosis, apoptotic cell death is energy dependent, genetically controlled 170 
and morphologically distinct (i.e., developing apoptotic bodies, cell shrinking and 171 
nuclear condensation) (Figure 1) [31].   Apoptosis has been identified in primary breast 172 
tumors treated with neoadjuvant chemotherapy in situ.  Studies by Chang et al. (2000) 173 
and Ellis et al. (1997) demonstrated that there was an increase in apoptosis in 174 
responsive tumors and detected as early as 24 hours after the administration of 175 
chemotherapy [32, 33].  Chang et al. (2000) showed that increased apoptosis was 176 
linked to complete pathologic response where there was no residual or palpable 177 
disease after therapy [32].  Buchholz et al. (2003) also measured the apoptotic activity 178 
in breast tumors after 48 hours of chemotherapy.  Patients who had a 25% increase in 179 
the apoptotic activity had gone on to achieve pCR.  The apoptotic activity was 180 
significantly different to patients who did not achieve pCR (P<0.015)  [34].   Although 181 
only a small number of clinical studies have examined serial breast tumor biopsies to 182 
measure apoptosis in situ, the findings to date have indicated agreement with 183 
laboratory-based experiments for other tumor types in vitro [35-37].   184 
Alterations in the tumor’s vascular organization are also important hallmarks of 185 
chemoefficacy.   An important property of malignancies is the abnormal vascular 186 
architecture, which contributes to a spatially heterogeneous environment [38].   The 187 
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vascular morphology and layout have been well studied; blood vessels are 188 
disorganized, distributed unevenly, immature and leaky, which also affects the tumor’s 189 
response to treatment [39].  The tortuous vessel formations have been shown 190 
previously to inhibit drug efficacy by secreting cell-protective factors against 191 
chemotherapy insult [40, 41] .  Additionally, abnormal morphologies such as variable 192 
vessel diameters and weak junctions in the vessel walls have been demonstrated to 193 
inhibit efficacious drug delivery since leaky vessels mitigate drug concentrations in 194 
tumors for effective therapeutic effect [42, 43].  Additionally, the uneven vascular 195 
scaffold creates areas with variable and high interstitial fluid pressure, which resists the 196 
transport of cytotoxic agents into the stroma [28, 41, 44].    Solid tumors that respond to 197 
chemotherapy exhibit characteristic patterns in their vessel reorganization  [38].  Jain et 198 
al. (2005) described these patterns as vascular “normalization” by which the vascular 199 
architecture is reconfigured to eliminate inefficient, saccular, leaky and immature vessel 200 
formations (Figure 2) [38].  This results in improved oxygen delivery and cytotoxic 201 
efficacy.   In highly responsive tumors, the vasculature eventually regresses and limits 202 
the nutrient supply to tumor cells [45].  The net effect is a regression in the vascular 203 
density in tumors.  Consequently, this leads to spatial and structural changes in the 204 
tumor. 205 
Taken together, the important characteristics of tumor response to chemotherapy 206 
include vascular normalization and regression, cell death and changes in the tissue 207 
composition. These characteristics are the focus of detection using imaging biomarkers.   208 
 209 
 9 
IMAGING BIOMARKERS AS INDICATORS FOR 210 
CHEMORESPONSE 211 
 212 
Conventional Imaging Methods 213 
Conventional imaging from magnetic resonance imaging (MRI), computed 214 
tomography (CT) and B-mode ultrasound (US) are used to measure tumor size changes 215 
during NAC.  Radiological response criteria are graded using RECIST 1.1 (Response 216 
Criteria in Solid Tumors) guidelines [46].  However, major limitations for measuring 217 
tumor size changes include: 1) dependency on user expertise to identify the lesion; 2) 218 
distinguishing tumor boundaries on multiple scan planes in the case of MRI and CT; 3) 219 
a change in the tumor’s size may take several weeks before it is detectable, which limits 220 
early detection and; 4) size measurements may be conflated with fibrosis, collagen, fatty 221 
tissue and inflammation in the breast.   222 
Quantitative imaging biomarkers addresses the limitations associated with 223 
conventional imaging.  Quantitative imaging biomarker techniques measure the 224 
biological and functional tumor features previously outlined such as cell metabolism, cell 225 
death and vascular reorganization. The overall purpose of investigating imaging 226 
biomarkers in oncological studies is to achieve optimal accuracy of imaging biomarker 227 
features with pathology endpoints such as pCR.   Recent imaging methods are 228 
described below and biomarker measurements are outlined in Table 1.     229 
Magnetic Resonance Imaging Biomarkers 230 
 MRI-based imaging biomarkers can be extracted from diffusion-weighted imaging 231 
(DWI-MRI), dynamic contrast enhanced imaging (DCE-MRI), blood-oxygen level 232 
dependent imaging (BOLD-MRI) and MRI-spectroscopy (MRI-SPEC).    These 233 
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techniques are capable of mapping tumor oxygenation, vascularization, metabolism and 234 
the extracellular matrix as response markers to neoadjuvant chemotherapy in breast 235 
cancer (Table 1).  Diffusion-weighted MR measures the diffusion of water molecules 236 
(i.e. Brownian motion) in tissue [47, 48].  Tissue contrast can be displayed in DW-MRI 237 
imaging based on areas of high and low water diffusion; where areas of low water 238 
motion (i.e. tumors) demonstrate an enhanced signal.  Previous studies have 239 
demonstrated that areas with low water motion are associated with malignant tissue due 240 
to densely arranged cells which limit the motion of water in the extracellular space [48].   241 
Extrinsic contrast imaging techniques include dynamic contrast enhanced imaging 242 
(DCE-MRI) which detects the concentration of an injected contrast agent (gadolinium 243 
chelate) in the intravascular and extravascular space using primarily T1-weighted 244 
signals [47].  DCE-MRI images provide information on tumor vascularity and blood flow 245 
and measure the gadolinium “wash-in” and “wash-out”.   Tumors preferentially 246 
accumulate gadolinium from an increased vascular supply compared to normal tissue, 247 
and therefore demonstrate an enhanced signal in MRI [49].  Blood-oxygen level 248 
dependent (BOLD-MRI) imaging is also used to measure the tumor vascularity, and 249 
tumor oxygenation.  This is accomplished by detecting deoxyhemoglobin, which is 250 
paramagnetic and therefore results in signal loss in T2-weighted images [50].   251 
 252 
     Positron-Emission Tomography (PET) 253 
 PET imaging monitors metabolic activity by tracking the cellular uptake of a 254 
glucose analogue, [18F]-fluorodeoxyglucose (FDG).  FDG is injected intravenously, 255 
transported into cells like glucose, and is labelled with a radioactive tracer that 256 
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demonstrates radioactive decay, permitting PET imaging to map metabolic activity in 257 
tissue.  Increased FDG-uptake (standard uptake value, SUV) has been demonstrated in 258 
tumors since tumor metabolism is greater compared to normal tissue. PET imaging can, 259 
therefore, serve to identify the extent of malignancies [51].  PET imaging is achieved 260 
with the release of a gamma-ray photon that is detected by a photon-detection device 261 
during radioactive decay, known as positron-electron annihilation.  Another radiotracer 262 
used in PET is the radionuclide 15O-H2O, which is used to measure tumor blood flow; 263 
where the distribution of water can be equated to blood activity in blood vessels [52].   264 
Previous work from Duch et al. (2009) showed that the intratreatment change in SUV 265 
(DSUV, 2 cycles of chemotherapy) differentiated between pathologic response groups 266 
(responders vs. non-responders) with a sensitivity of 77% and specificity of 80%, using 267 
a cut-off value of 40% [53].  268 
 269 
Diffuse Optical Spectroscopy (DOS)  270 
 Diffuse optical spectroscopy (DOS) imaging can measure tumor response to 271 
chemotherapy by focusing on changes in tissue composition [54-56].  Maps of tumor 272 
physiological features, such as hemoglobin, are computed from tissue-optical properties 273 
that are based on near-infrared optical scattering and absorption within the near-infrared 274 
spectrum (600-1100 nm) [57].  For breast tissue, significant optical absorbers include 275 
oxy-hemoglobin (HbO2), deoxy-hemoglobin (Hb), water (H2O) and lipids (Li) [57].   276 
Chromophore concentrations can be estimated by measuring the absorption co-efficient 277 
[µa] and using Beer’s law equation [58].  Also, tissue optical parameters such as the 278 
reduced scattering co-efficient [µ¢s] can provide additional information on tissue 279 
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microstructure (~0.2 µm); corresponding to optical scattering effects from mitochondria 280 
and the cell nucleus [57, 59].   Other DOS parameters, such as the scatter power and 281 
scatter amplitude, calculated by using the power-law function, are representative of the 282 
tissue’s substructure, which is related to cellularity, cell arrangement, and light-scatterer 283 
spatial distributions [60].  As a result, DOS imaging can demonstrate a good sensitivity 284 
to the biochemical characteristics of breast tumors that undergo changes from 285 
neoadjuvant chemotherapy.  Previous work by Cerussi et al. (2011) indicated that 286 
hemoglobin-based parameters demonstrated significant differences between pCR vs. 287 
non-pCR patients (p<0.05) [58].  Early indicators of treatment response were reported 288 
by Robyler et al. (2011) and showed an “oxy-hemoglobin flare” in responders after one 289 
week of treatment [54].  In another study by Ueda et al. (2012), the baseline oxygen 290 
saturation demonstrated significant differences between pCR and non-pCR patients 291 
(p<0.01), and corresponded to a sensitivity and specificity of 75.0% and 73.3%, 292 
respectively [61].      293 
 294 
Ultrasound Imaging Biomarkers 295 
 Ultrasound imaging biomarkers are obtained by mechanical imaging such as 296 
elastography (which is considered semi-quantitative), or functional imaging such as 297 
power-Doppler ultrasound and quantitative ultrasound spectroscopy (QUS). Ultrasound 298 
elastography measures tissue stiffness, which characterizes tissue biomechanical 299 
properties.  Tumors are “stiffer” than the surrounding normal parenchyma because they 300 
are comprised of densely populated and rapidly dividing cells, as well as increased 301 
vasculature and fibroglandular components that alter its mechanical properties [62-64].  302 
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Tissue stiffness can be measured in terms of tissue stress and strain using shear-wave 303 
elastography or compression-based elastography.  Evans et al. (2013) reported that 304 
stiffer tumors were significantly correlated to a higher residual cancer burden index 305 
(RCBI), which indicates poor pathologic response at the end of chemotherapy (Pearson 306 
correlation coefficient=0.23, P<0.004) [65].  307 
Functional US-based imaging techniques include power Doppler imaging that 308 
assess tumor vasculature from the frequency shift and amplitude (power) of the 309 
ultrasound backscatter signal from scatterers in the blood vessels [66].  An emerging 310 
field includes quantitative ultrasound spectroscopy, which uses the spectral information 311 
of the ultrasound radiofrequency (RF) signals to characterize morphological changes in 312 
tumor cells associated with apoptosis caused by chemotherapy [37, 67].  To date, QUS 313 
has been used to measure intratreatment response; showing significant changes in the 314 
spectral parameters for chemoresponding patients as early as one week after treatment 315 
initiation [68].  Also, recent results have demonstrated that pre-treatment QUS 316 
parameters can predict NAC response in patients with an accuracy of 88%; while 317 
demonstrating a high correlation to survival outcomes [69].   318 
 319 
 320 
 321 
 322 
 323 
 324 
 325 
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Technique Biomarker Measurements Treatment Points Studied Ref. 
Magnetic Resonance Imaging  
DWI-MRI 
• Extracellular water motion 
• Tumor-cell density 
• Tissue micro-structure 
• Cell membrane integrity 
• Cell membrane permeability 
• Pre-treatment  
• Intratreatment 
• Post-chemotherapy 
[48] 
[47] 
[47] 
[70] 
[71] 
[50] 
[72] 
[73] 
[74] 
DCE-MRI • Vascular permeability 
• Dynamic blood flow 
BOLD 
• Tumor oxygenation 
• Tumor vascularity 
• Angiogenesis 
• Blood Volume 
• Blood Flow 
SPECT 
• Reduction in mitotic count 
• Tumor cellularity 
• Cell membrane integrity 
• Tumor metabolism 
• Tissue composition (lipid) 
 
Positron-Emission Tomography  
18F-FDG • Tumor metabolism • Pre-treatment 
• Intratreatment 
• Post-chemotherapy 
[75] 
[52] 
[75] 
15O-H2O • Tumor blood flow 
Diffuse Optical Spectroscopy  
DOS 
• Metabolism 
• Cell activity 
• Vascular Density 
• Edema 
• Breast tissue composition 
• Cellularity 
• Cell death and Morphology 
• Tissue contrast 
• Hypoxia 
• Pre-treatment 
• Intratreatment 
• Post-chemotherapy 
[57] 
[76] 
[58] 
[77] 
[60] 
[57] 
[60] 
[60] 
Ultrasound  
Elastography 
• Tumor progression 
• Extracellular matrix 
• Collagen crosslinking 
• Tissue composition (fibrosis) 
• Pre-treatment 
• Intratreatment 
• Post-chemotherapy 
[64] 
[62] 
[65] 
[78] 
[79] 
[79] 
[80] 
Power Doppler 
• Vascular blood flow 
• Blood perfusion 
• Vascularity 
QUS 
• Tumor Cell Death (Apoptosis) 
• Cell Morphology and 
Distribution 
Table 1.  Imaging biomarker studies have included MRI, PET imaging, DOS, and 326 
ultrasound based imaging.  The studies have included response assessment using 327 
various biological features at various stages of chemotherapy treatment: before 328 
treatment (pre-treatment), intratreatment, and post-treatment 329 
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IMAGE TEXTURE ANALYSIS AND MACHINE LEARNING 330 
 331 
 332 
Other imaging biomarker features can be extracted from image-texture analysis.  333 
Texture analysis refers to mathematical methods that can apply second-order statistical 334 
methods to yield texture features of an image. Feature-extraction methods, such as 335 
those based on grey-level co-occurrence matrices (GLCM), can be applied to compute 336 
the probabilities of relative pixel intensities of images from the spatial distribution of their 337 
voxels [81].    This is useful for quantifying image heterogeneities and their application 338 
has extended to discriminating benign vs. malignant breast lesions in breast 339 
radiographs [82].  Texture analysis has also been useful in X-ray mammography [83], 340 
MRI [84, 85], positron-emission tomography (PET) [86], and ultrasound [87] to identify 341 
malignant lesions and for discriminating and characterizing various tissue types [88].  In 342 
other breast studies, GLCM analysis has been under investigation for utility to classify 343 
benign and malignant lesions using planar (2D) and volumetric (3D) MRI images [84, 344 
89].  Additionally, GLCM analysis has been used to segment lesion borders of stellate 345 
(malignant) breast masses [90].  346 
For therapy evaluation, texture analysis has also been used to discriminate 347 
breast tumor response to NAC from various imaging modalities [82, 91, 92]. Texture 348 
features of the image carry important information about the tumor’s properties, 349 
corresponding to heterogeneity within the tumor itself [90].  Such techniques have been 350 
applied with computer-aided, machine-learning techniques for statistical modelling [93].  351 
Machine learning classification algorithms include support vector machines (SVM), k-352 
nearest neighbor (k-NN), naïve Bayes, and artificial neural networks (ANN) that can be 353 
used to classify response groups by pattern recognition and spatial probabilities within a 354 
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feature space.  These methods have recently been applied to quantitative ultrasound 355 
(QUS) imaging and have demonstrated high classification accuracy in responders and 356 
non-responders at early phases of NAC treatment [68].  These previous findings 357 
suggested that textural features can provide information on the microstructural 358 
biological characteristics carried in the parametric layout, not otherwise detected using 359 
the mean parametric measurements [68].    360 
 361 
STATUS OF IMAGING BIOMARKERS FOR PERSONALIZED 362 
MEDICINE IN BREAST CANCER 363 
 364 
 Adopting imaging biomarkers as a decision-making tool in the clinic involves 365 
several steps that originate with laboratory investigations and, following the translational 366 
research pathway progress to clinical trials.  Here, it is pertinent to discuss the current 367 
demand from patients and clinicians for imaging biomarkers in the clinic, the 368 
translational obstacles and how generalizable imaging biomarker models are for 369 
measuring breast cancer response to NAC.  The demand for imaging biomarkers has 370 
been highlighted recently by a UK-based working group that identified critical research 371 
gaps and translational priorities for breast cancer.  Their report highlighted the 372 
importance of exploiting both biospecimen-based markers and imaging for guiding 373 
breast cancer treatment.  Below are the major considerations outlined by their group 374 
[94]: 375 
 376 
1. Selection of therapies should be offered on an individual basis and using level-377 
one evidence.  Personalized treatments are the best approach.   Important 378 
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considerations include optimizing the treatment time-course from individual 379 
tumor and patient data.  Currently, overtreatment is a clinical challenge. 380 
2. An assessment of the tumor’s underlying biology is essential.  Tumor metrics 381 
may help assess the patient’s metastatic risk and predict drug resistance. The 382 
tumor’s behaviors from its cellular characteristics, molecular features, 383 
angiogenic pathways and stromal conditions (i.e. hypoxia, altered metabolism) 384 
may aid in understanding the impact on therapeutic interventions.  This may be 385 
achieved by using functional and metabolic medical imaging modalities.   386 
3.  Clinical decision-making tools will be integral in the management and treatment 387 
of breast cancer patients.  For example, imaging biomarkers could be used to 388 
predict prognosis and response to chemotherapy.  Imaging modalities will 389 
permit potentially non-invasive, serial measurements that monitor the dynamic 390 
tumor changes over time.          391 
4. High risk populations include triple negative breast cancer patients and 392 
research needs to address prognostic and predictive biomarkers for this patient 393 
population.  In general, tumor heterogeneity is a treatment challenge and 394 
stratification of patients is needed in future studies for better treatment 395 
strategies.  396 
5. Both clinical and financial effectiveness should be considered while 397 
implementing new decision-making tools for clinical use.  398 
 399 
The need for biomarkers in medicine has been identified for decades.  In the early 400 
2000s, the human genome project was completed to identify and map out thousands of 401 
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genes in human cells [95, 96].   Since then, great efforts have been made in cataloguing 402 
and identifying gene signatures involved in disease progression, drug metabolism and 403 
treatment resistance across several disorders like cardiovascular disease, infectious 404 
diseases and cancer [97].  A major focus in genomic oncology has been to identify 405 
predictors for chemotherapy-resistance in breast cancer [97, 98].  Indeed, thousands of 406 
gene markers have been studied as predictors to therapy response in cancer.  Yet, one 407 
of the most notable works include the validation of a 21-gene assay (Oncotype-DX) that 408 
predicts the probability that patients would benefit from adjuvant chemotherapy.  The 409 
assay includes genes that have been shown to potentiate higher prognostic risk factors 410 
[98].  The 21-gene signatures have undergone validation in over 10,000 patients.  The 411 
NSABP study B-14 trial demonstrated that Oncotype DX was shown to predict 412 
recurrence in patients treated with Tamoxifen [99]; while a parallel study (NSABP study 413 
B-20) showed the benefit of the assay for predicting chemotherapy response [100].   414 
The benefits from Oncotype DX biomarker testing are recognized as useful for a subset 415 
of breast patients; namely, in hormone-receptor-positive, Her2-negative, axillary node-416 
negative breast cancer [101, 102].  The Oncotype-DX assay is one example of how 417 
specimen-derived biomarker discoveries have been adopted by clinicians to guide 418 
treatment and enhance personalized medicine.  It also demonstrates the several 419 
validation hurdles that biomarker studies undergo before clinical acceptance and that 420 
biomarkers themselves may not be generalizable for all breast cancer subtypes. In 421 
comparison to imaging biomarkers, no such imaging biomarkers have reached the 422 
clinical adoption stage comparable to biospecimen biomarkers to guide treatment 423 
decisions like Oncotype DX for breast cancer.  424 
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Despite the significant efforts to investigate imaging biomarkers for clinical use, 425 
many of the identified biomarkers have not surpassed initial research hypothesis 426 
testing; thus, never having reached large-scale clinical trials for robust clinical validation.  427 
In fact, emerging research that could potentially guide treatments often falls through two 428 
major translational gaps [103].  These gaps were previously outlined by Cancer 429 
Research UK (CRUK) and the European Organization for Research and Treatment of 430 
Cancer (EORTC) working group; specifically: 1) validation of the biomarkers through 431 
initial scientific testing (i.e. are the imaging biomarkers robustly tested and capable of 432 
answering the scientific or medical hypothesis?) and; 2) validation of the imaging 433 
biomarkers as a clinical-decision tool (i.e. have the imaging biomarkers undergone the 434 
appropriate clinical trial to be used and generalized for patients?). Integrating and using 435 
imaging biomarkers in practice necessitates marker validation, generalizability and cost-436 
benefit analysis [94, 103].  To date, imaging biomarkers have surpassed the first 437 
translational gap to address scientific hypothesis testing, but have yet to succeed in the 438 
subsequent clinical research testing stage for robust validation.  Major limitations 439 
include repeatability and reproducibility of results and the standardization of assessing 440 
tumor response, i.e., imaging parameters and protocols, time intervals and establishing 441 
test cut-off points. 442 
Taken together, imaging biomarkers are proving to have great potential for use in 443 
locally advanced breast cancer treatment.  The limitations for routine clinical use 444 
involves the need for multicenter trials for validation and improvements on study design 445 
and laying out a standard imaging protocol.  To address these, this will involve 446 
determining the optimal imaging time-points to assess intratreatment response and 447 
 20 
establishing the appropriate test cut-off points that classify patients into the responder 448 
vs. non-responder category. The aim, nevertheless, is to develop imaging biomarkers to 449 
permit response-predictive or response-adaptive therapy to move away from a one-size 450 
fits all approach towards personalized cancer care. 451 
 452 
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 Figure 1 716 
 717 
 718 
 719 
Figure 1:  Apoptosis in cancer cells.  Apoptosis is characterized as an energy 720 
dependent mechanism where cells undergo programmed morphological changes.  721 
Chemotherapies induce apoptosis in tumor cells and this results in cell shrinking and 722 
nuclear restructuring such as karyolysis, pyknosis and karyorhexis. 723 
  724 
 725 
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 727 
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 729 
 730 
 731 
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Figure 2 735 
 736 
 737 
Figure 2:   A comparison of the vascular organization. A.  Normal tissue exhibits well-738 
organized vasculature, which permit exchange of biomolecules and gas (arrows).  B.  739 
Untreated tumors show high density vasculature and do not permit free exchange of 740 
biomolecules and gasses.  C.  Normalized tumors demonstrate greater organization 741 
closer to that of normal tissue.  D.  In regressed tumors, the vasculature may be absent, 742 
or minimal. (Figure adapted from Jain et al., 2005 [45]).   743 
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